1
|
Piya MK, Tahrani AA and Barnett AH:
Emerging treatment options for type 2 diabetes. Br J Clin
Pharmacol. 70:631–644. 2010.PubMed/NCBI View Article : Google Scholar
|
2
|
Drucker DJ and Nauck MA: The incretin
system: Glucagon-like peptide-1 receptor agonists and dipeptidyl
peptidase-4 inhibitors in type 2 diabetes. Lancet. 368:1696–1705.
2006.PubMed/NCBI View Article : Google Scholar
|
3
|
Bo A: GLP-1 for type 2 diabetes. Exp Cell
Res. 317:1239–1245. 2011.PubMed/NCBI View Article : Google Scholar
|
4
|
Malik DK, Baboota S, Ahuja A, Hasan S and
Ali J: Recent advances in protein and peptide drug delivery
systems. Curr Drug Deliv. 4:141–151. 2007.PubMed/NCBI View Article : Google Scholar
|
5
|
Pawar R, Ben-Ari A and Domb AJ: Protein
and peptide parenteral controlled delivery. Expert Opin Biol Ther.
4:1203–1212. 2004.PubMed/NCBI View Article : Google Scholar
|
6
|
Perry CM: Liraglutide. Drugs.
71:2347–2373. 2011.PubMed/NCBI View Article : Google Scholar
|
7
|
Dunning BE, Foley JE and Ahrén B: Alpha
cell function in health and disease: Influence of glucagon-like
peptide-1. Diabetologia. 48:1700–1713. 2005.PubMed/NCBI View Article : Google Scholar
|
8
|
Wang Q and Brubaker PL: Glucagon-like
peptide-1 treatment delays the onset of diabetes in 8 week-old
db/db mice. Diabetologia. 45:1263–1273. 2002.PubMed/NCBI View Article : Google Scholar
|
9
|
Ding X, Saxena NK, Lin S, Gupta NA and
Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor
agonist, reverses hepatic steatosis in ob/ob mice. Hepatology.
43:173–181. 2006.PubMed/NCBI View Article : Google Scholar
|
10
|
Del Prato S and Tiengo A: The importance
of first-phase insulin secretion: Implications for the therapy of
type 2 diabetes mellitus. Diabetes Metab Res Rev. 17:164–174.
2001.PubMed/NCBI View
Article : Google Scholar
|
11
|
Li HJ, Ma Y, Chen Y, Sang Y, Zhou T, Qiu
M, Huang X, Zhou C and Su Z: A protease-based strategy for the
controlled release of therapeutic peptides. Angew Chem Int Ed Engl.
49:4930–4933. 2010.PubMed/NCBI View Article : Google Scholar
|
12
|
Berglund O: Different dynamics of insulin
secretion in the perfused pancreas of mouse and rat. Acta
Endocrinol (Copenh). 93(54)1980.PubMed/NCBI
|
13
|
Voss EM, Bina DM, Mcneil LAD, Johnson ML
and Cembrowski GS: Determining acceptability of blood glucose
meters: Evaluating a blood glucose testing system. Lab Med.
27:679–682. 1996. View Article : Google Scholar
|
14
|
Collins S, Martin TL, Surwit RS and
Robidoux J: Genetic vulnerability to diet-induced obesity in the
C57BL/6J mouse: Physiological and molecular characteristics.
Physiol Behav. 81:243–248. 2004.PubMed/NCBI View Article : Google Scholar
|
15
|
Pan Z: Study of the Biological
Characteristics of Sibp: KM mouse. Acta Laboratorium Animalisentia
Sinica. 1995.
|
16
|
Pharmacopoeia of the People's Republic of
China: Chemical Industry Press, 2015.
|
17
|
Lenzen S: The mechanisms of alloxan- and
streptozotocin-induced diabetes. Diabetologia. 51:216–226.
2008.PubMed/NCBI View Article : Google Scholar
|
18
|
Ramanadham S, Doroudian A and McNeill JH:
Myocardial and metabolic abnormalities in streptozotocin-diabetic
Wistar and Wistar-Kyoto rats. Can J Cardiol. 6:75–82.
1990.PubMed/NCBI
|